Cargando…
MYCMI-7: A Small MYC-Binding Compound that Inhibits MYC: MAX Interaction and Tumor Growth in a MYC-Dependent Manner
Deregulated expression of MYC family oncogenes occurs frequently in human cancer and is often associated with aggressive disease and poor prognosis. While MYC is a highly warranted target, it has been considered “undruggable,” and no specific anti-MYC drugs are available in the clinic. We recently i...
Autores principales: | Castell, Alina, Yan, Qinzi, Fawkner, Karin, Bazzar, Wesam, Zhang, Fan, Wickström, Malin, Alzrigat, Mohammad, Franco, Marcela, Krona, Cecilia, Cameron, Donald P., Dyberg, Cecilia, Olsen, Thale Kristin, Verschut, Vasiliki, Schmidt, Linnéa, Lim, Sheryl Y., Mahmoud, Loay, Hydbring, Per, Lehmann, Sören, Baranello, Laura, Nelander, Sven, Johnsen, John Inge, Larsson, Lars-Gunnar |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Association for Cancer Research
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9980915/ https://www.ncbi.nlm.nih.gov/pubmed/36874405 http://dx.doi.org/10.1158/2767-9764.CRC-21-0019 |
Ejemplares similares
-
A selective high affinity MYC-binding compound inhibits MYC:MAX interaction and MYC-dependent tumor cell proliferation
por: Castell, Alina, et al.
Publicado: (2018) -
Pharmacological inactivation of CDK2 inhibits MYC/BCL-XL-driven leukemia in vivo through induction of cellular senescence
por: Bazzar, Wesam, et al.
Publicado: (2020) -
Max deletion destabilizes MYC protein and abrogates Eµ-Myc lymphomagenesis
por: Mathsyaraja, Haritha, et al.
Publicado: (2019) -
MYC Modulation around the CDK2/p27/SKP2 Axis
por: Hydbring, Per, et al.
Publicado: (2017) -
MYC is downregulated by a mitochondrial checkpoint mechanism
por: Zhang, Xiaonan, et al.
Publicado: (2017)